Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Debt (2017 - 2021)

Historic Total Debt for Sunshine Biopharma (SBFM) over the last 5 years, with Q4 2021 value amounting to $1.9 million.

  • Sunshine Biopharma's Total Debt rose 10020.95% to $1.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.9 million, marking a year-over-year increase of 10020.95%. This contributed to the annual value of $1.9 million for FY2021, which is 10020.95% up from last year.
  • Per Sunshine Biopharma's latest filing, its Total Debt stood at $1.9 million for Q4 2021, which was up 10020.95% from $3.2 million recorded in Q3 2021.
  • Sunshine Biopharma's 5-year Total Debt high stood at $3.2 million for Q3 2021, and its period low was $27541.0 during Q3 2019.
  • Its 5-year average for Total Debt is $897399.7, with a median of $312566.0 in 2018.
  • In the last 5 years, Sunshine Biopharma's Total Debt plummeted by 9118.87% in 2019 and then soared by 314859.25% in 2021.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Total Debt stood at $79710.0 in 2017, then surged by 289.81% to $310718.0 in 2018, then plummeted by 91.14% to $27541.0 in 2019, then surged by 3345.79% to $949006.0 in 2020, then skyrocketed by 100.21% to $1.9 million in 2021.
  • Its Total Debt stands at $1.9 million for Q4 2021, versus $3.2 million for Q3 2021 and $2.1 million for Q2 2021.